Every material Form 8-K ACHIEVE LIFE SCIENCES, INC. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Achieve Life Sciences said its board appointed Benjamin Halladay as Chief Financial Officer effective October 5, 2026, replacing Mark Oki, who is stepping down from the role on the same date. Mr. Halladay previously served as CFO of Esperion Therapeutics from November 2022 until September 2026, and the company said Mr. Oki's departure is not related to any disagreement over its financial statements or disclosures.
Benjamin Halladay appointed CFO and principal financial officer, effective October 5, 2026
Mark Oki steps down as CFO effective October 5, 2026; the company says there was no disagreement over financial statements or disclosures
Halladay offer letter includes $525,000 base salary, bonus of up to 40% of base salary, option for up to 200,000 shares and 200,000 restricted stock units
Full employment agreement text to be filed with the Form 10-Q for the quarter ending September 30, 2026
On August 14, 2026, Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell up to $150.0 million of common stock at its sole discretion. Sales would dilute existing shareholders, and the company says proceeds will fund cytisinicline commercialization, a Phase 3 trial for e-cigarette cessation, and working capital.
Up to $150.0 million of common stock may be sold through Jefferies as sales agent, at the company's discretion
Jefferies may receive compensation of up to 3.0% of aggregate gross proceeds, plus reimbursement of certain expenses
Shares are issued under a Form S-3 registration statement filed January 23, 2026, and a prospectus supplement filed August 14, 2026
The company has no obligation to sell shares and may suspend offers at any time
Achieve Life Sciences reported a second-quarter 2026 net loss of $74.8 million, up from $12.7 million a year earlier, with no revenue reported. The loss includes a non-cash $48.7 million charge tied to the change in fair value of warrant liabilities from its private placement, and the company said it plans to resubmit its cytisinicline NDA in the fourth quarter of 2026 after a June 20, 2026 Complete Response Letter from the FDA.
Q2 2026 net loss was $74.8 million, or $0.80 per share, versus a net loss of $12.7 million, or $0.37 per share, in Q2 2025.
The quarter includes a non-cash $48.7 million charge related to changes in the fair value of warrant liabilities from the private placement.
Total operating expenses were $18.4 million versus $12.6 million a year earlier; cash, cash equivalents and marketable securities were $187.3 million as of June 30, 2026.
On June 20, 2026, the FDA issued a Complete Response Letter; the company plans NDA resubmission in Q4 2026 and anticipates potential approval in the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ACHIEVE LIFE SCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →